NASH kNOWledge Launches Spanish Language Website to Address Community Need for Those at Risk for Nonalcoholic Liver Disease
June 28, 2022 09:00 ET | NASH EDUCATION
PITTSBURGH, June 28, 2022 (GLOBE NEWSWIRE) -- NASH kNOWledge today announced the launch of HigadoGraso.org, a new Spanish language website that provides information for those at-risk for...
Madrigal logo.jpg
Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™
June 25, 2022 09:00 ET | Madrigal Pharmaceuticals, Inc.
Late-breaking data from the double-blind portion of the noninvasive Phase 3 MAESTRO NAFLD-1 study show resmetirom to be safe and well-tolerated and to reduce liver fat, fibrosis measures on FibroScan...
Inventiva to host a webcast with Key Opinion Leaders following the EASL International Liver Congress™ 2022
June 16, 2022 16:00 ET | INVENTIVA
Update on Inventiva’s NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH and fibrosis (stage F2/F3) non-cirrhotic by Prof. Sven FrancqueUpdate on the current NASH landscape...
Inventiva organise un webcast avec des leaders d’opinion à l’occasion de l’EASL International Liver Congress™ 2022
June 16, 2022 16:00 ET | INVENTIVA
Point sur l’étude clinique de Phase III NATiV3 d'Inventiva évaluant lanifibranor chez les patients atteints de NASH et de fibrose (stade F2/F3) non cirrhotique par le Prof. Sven FrancquePoint sur le...
Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2022
June 09, 2022 16:00 ET | INVENTIVA
Three poster presentations showing the beneficial effects of lanifibranor on markers of cardiometabolic health in patients with non-cirrhotic NASH fibrosis independent of weight gain observed.the...
Inventiva annonce la présentation de trois abstracts scientifiques lors de l’EASL International Liver Congress™ 2022
June 09, 2022 16:00 ET | INVENTIVA
Trois présentations par poster démontrant : les effets bénéfiques de lanifibranor sur les marqueurs de la santé cardiométabolique chez les patients atteints de NASH avec fibrose non cirrhotique,...
Logo.jpg
Endonovo Therapeutics Announces LOI to Acquire Specialty Construction Company
June 09, 2022 14:02 ET | Endonovo Therapeutics, Inc.
Los Angeles, CA, June 09, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTCQB:ENDV) today announced a Letter of Intent to purchase a highly-regarded market leading specialty concrete services...
International NASH Day Highlights a Common – But Unfamiliar – Liver Disease
June 08, 2022 18:04 ET | Global Liver Institute
Washington, D.C., June 08, 2022 (GLOBE NEWSWIRE) -- Global Liver Institute (GLI) calls attention to NASH by leading the 5th annual International NASH Day on June 9. The number of people with this...
Madrigal logo.jpg
Madrigal Pharmaceuticals Supports International NASH Day on June 9
June 06, 2022 08:00 ET | Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., June 06, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic...
Madrigal logo.jpg
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
June 02, 2022 08:00 ET | Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic...